Back to Trials
NCT05842603NARecruiting

I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

Massachusetts General Hospital

Start Date

3/1/2024

Completion Date

1/1/2027

Summary

The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods. The name of the intervention used in this research study is: Cardiac Lifestyle Program (a 12-week, tailored nutrition and physical activity program)

Detailed Description

This is a single-arm, prospective pilot study that will enroll eligible Myeloproliferative Neoplasms (MPN) patients in a 12-week exercise and nutrition-based Cardiac Lifestyle Program (CLP). This research study is a Feasibility Study, which is the first time investigators are examining this exercise program in myeloproliferative disorder patients. Study procedures include screening for eligibility, an in-clinic visit, questionnaires, program group classes, and blood work. Participation in this research study is expected to last 12 weeks. It is expected that about 30 people will take part in this research study.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: -≥18 years of age * Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Must have at least one cardiovascular risk factor including: Body mass index (BMI) \>25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study. Exclusion Criteria: \-- MF patients with intermediate-2 or high-risk disease by DIPSS * ECOG performance status \>2. * Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.

Interventions

BEHAVIORAL

Cardiac Lifestyle Program

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Myeloproliferative DisordersLeukemia

Locations

Brigham and Women's Hospital

Boston, Massachusetts 02215

United States

Dana-Farber Cancer Institute

Boston, Massachusetts 02215

United States

Massachusetts General Hospital Cancer Center

Boston, Massachusetts 02215

United States